PriceTargets.com logo

NASDAQ:IBRX - ImmunityBio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 284.62 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.50 As of 11/26/2021 05:00 PM ET
▲ +0.15 (2.36%)

This chart shows the closing price for IBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunityBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBRX

Analyst Price Target is $25.00
▲ +284.62% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmunityBio in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 284.62% upside from the last price of $6.50.

This chart shows the closing price for IBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in ImmunityBio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2021Piper SandlerBoost Price TargetOverweight$18.00 ➝ $25.00Medium
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2021
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
7/31/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
9/29/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 11 very negative mentions
Mentions as of
10/29/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2021

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

ImmunityBio logo
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.
Read More

Today's Range

Now: $6.50
Low: $6.30
High: $7.10

50 Day Range

MA: $8.55
Low: $6.09
High: $10.71

52 Week Range

Now: $6.50
Low: $5.78
High: $45.42

Volume

1,628,178 shs

Average Volume

1,193,808 shs

Market Capitalization

$2.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunityBio?

The following Wall Street sell-side analysts have issued reports on ImmunityBio in the last twelve months: Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for IBRX.

What is the current price target for ImmunityBio?

1 Wall Street analysts have set twelve-month price targets for ImmunityBio in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 284.6%. Piper Sandler has the highest price target set, predicting IBRX will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $25.00 for ImmunityBio in the next year.
View the latest price targets for IBRX.

What is the current consensus analyst rating for ImmunityBio?

ImmunityBio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IBRX will outperform the market and that investors should add to their positions of ImmunityBio.
View the latest ratings for IBRX.

How do I contact ImmunityBio's investor relations team?

ImmunityBio's physical mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The company's listed phone number is (844) 696-5235 and its investor relations email address is [email protected] The official website for ImmunityBio is immunitybio.com.